Showing results (111-120 of 145) with videos related to
Sort By:
Pageof 15
BMC Cancer|February 1, 2018
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in SpainEdurne Arriola, Ramón García Gómez, Pilar Diz, et al.Cancers|March 28, 2024
Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal PermeabilityAlba Moratiel-Pellitero, María Zapata-García, Marta Gascón-Ruiz, et al.Frontiers in Oncology|January 1, 2025
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter studyAida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, et al.Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.Translational Lung Cancer Research|May 19, 2025
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN studyMar Varela, Cristina Teixidó, Carlos Álvarez-Fernández, et al.Cancer Medicine|July 23, 2021
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technologyPilar Garrido, Luis Paz-Ares, Margarita Majem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancerEnriqueta Felip, Rafael Rosell, José Antonio Maestre, et al.Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistanceJon Zugazagoitia, Ana Gómez-Rueda, Eloisa Jantus-Lewintre, et al.Clinical Lung Cancer|June 26, 2004
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancerVicente Alberola, Carme Sarries, Rafael Rosell, et al.American Journal of Clinical Oncology|October 11, 2008
Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanomaRaquel Andrés, Jose I Mayordomo, Carmen Visus, et al.Pageof 15